VB
Therapeutic Areas
Johnson & Johnson Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Talquetamab | Multiple Myeloma | Phase 3 |
| Nipocalimab | Generalized Myasthenia Gravis | Phase 3 |
| JNJ-2113 | Plaque Psoriasis | Phase 3 |
| JNJ-4804 | C. diff Prevention | Phase 3 |
| JNJ-77242113 | Psoriasis | Phase 3 |
| JNJ-3989 | Chronic Hepatitis B | Phase 2 |
| CARVYKTI® (ciltacabtagene autoleucel) | Multiple Myeloma | Phase 3 |
| Erdafitinib | Urothelial Carcinoma | Phase 3 |
Leadership Team at Johnson & Johnson
JD
Joaquin Duato
Chairman and Chief Executive Officer
JR
John Reed, M.D., Ph.D.
EVP, Innovative Medicine R&D
TS
Timothy Schmid
EVP, MedTech Worldwide Chairman
JJ
Joseph J. Wolk
EVP and Chief Financial Officer
PF
Peter Fasolo, Ph.D.
EVP, Chief Human Resources Officer